INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE

Authors :: Andres Forero-Torres
Alex F. Herrera
Leila Alland
Cassandra Choe-Juliak
A. Rodriguez Izquierdo
Craig B. Reeder
Andras Strassz
Sumana Devata
Sylvia Schwarz
Kim Prier
P. Armand
Ramón García-Sanz
Eva Domingo-Domenech
S. M. Ansell
Amitkumar Mehta
Robert W. Chen
Izidore S. Lossos
Nancy L. Bartlett
Taimur Sher
Source :: Hematological Oncology. 37:177-178
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Hematology
General Medicine
Pembrolizumab
Internal medicine
Relapsed refractory
medicine
Hodgkin lymphoma
In patient
Brentuximab vedotin
business
medicine.drug

Tools